Lucas Research, Inc.

The trials here

What the 10 trials at this site are about, from their registry records.

Conditions

• Obesity9 trials
• Type 2 diabetes4 trials
• High blood pressure1 trial

Phase

• Phase 210 trials

Status

• Completed6 trials
• Recruiting2 trials
• Not yet recruiting1 trial
• Terminated1 trial

Lead sponsor

• Eli Lilly and Company8 trials
• Mineralys Therapeutics Inc.1 trial
• Zealand Pharma1 trial

Running trials

• Not yet recruiting

  A Study to Investigate the Effect of LY4086940 Versus Placebo in Participants With Obesity or Overweight and Without Type 2 Diabetes

  NCT07890376· Phase 2· Eli Lilly and Company· Source

  Contact: Joseph Maides (principal investigator)

• Recruiting

  A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight

  NCT07589608· Phase 2· Eli Lilly and Company· Source

  Contact: Joseph Maides (principal investigator)

• Recruiting

  A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight

  NCT06143956· Phase 2· Eli Lilly and Company· Source

  Contact: Joseph Maides (principal investigator)

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Obesity3 recruiting
• Type 2 diabetes2 recruiting

Closed trials

• Terminated

  A Study of LY3549492 in Adults With Obesity or Overweight With Type 2 Diabetes

  NCT07030868· Phase 2· Eli Lilly and Company· Source

• Completed

  Once-weekly Petrelintide Versus Placebo for Obesity or Overweight With Co-morbidities

  NCT06662539· Phase 2· Zealand Pharma· Source

• Completed

  A Study to Investigate Weight Management With LY3549492 Compared With Placebo in Adult Participants With Obesity or Overweight

  NCT06683508· Phase 2· Eli Lilly and Company· Source

• Completed

  A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes

  NCT06603571· Phase 2· Eli Lilly and Company· Source

• Completed

  A Study of LY3841136 Compared With Placebo in Adult Participants With Obesity or Overweight

  NCT06230523· Phase 2· Eli Lilly and Company· Source

• Completed

  A Study of LY3305677 Compared With Placebo in Adult Participants With Obesity or Overweight

  NCT06124807· Phase 2· Eli Lilly and Company· Source

• Completed

  A Pivotal Study to Evaluate the Efficacy of Lorundrostat in Subjects With Uncontrolled Hypertension on a Standardized Antihypertensive Medication Regimen

  NCT05769608· Phase 2· Mineralys Therapeutics Inc.· Source